[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470365":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":41,"centralContacts":46,"locations":51,"responsibleParty":79,"collaborators":40,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":40,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":40,"studyType":95,"phases":96,"briefSummary":99,"conditions":100,"keywords":40,"overallStatus":53,"whyStopped":40,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"The First Affiliated Hospital of Soochow University","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment (azacytidine+venetoclax)","EXPERIMENTAL","Participants will receive azacytidine QD, on Days 1-5 and venetoclax QD, on Days 1-14 of each 28-day cycle for 8 cycles.",[13,14,15],"Drug: Azacitidine","Drug: Venetoclax","Other: Supportive care",{"label":17,"type":10,"description":18,"interventionNames":19},"Comparator ( best supportive care)","Participants will receive observation and supportive care during remission.",[15],[21,28,36],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Azacitidine","Given SC",[9],[27],"5-Azacytidine",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Venetoclax","Given PO",[9],[33,34,35],"ABT-199","GDC-0199","Venclexta",{"type":6,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Supportive care","Patients will receive disease monitoring and supportive care for any complication.",[17,9],null,[42],{"name":43,"affiliation":44,"role":45},"Suning Chen","First Affiliated Hospital of Soochow University","PRINCIPAL_INVESTIGATOR",[47],{"name":43,"role":48,"phone":49,"phoneExt":40,"email":50},"CONTACT","+86-13814881746","chensuning@sina.com",[52,69],{"facility":44,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","Suzhou","Jiangsu","215000","China","CN",{"type":60,"coordinates":61},"Point",[62,63],120.59538,31.30408,{"lat":63,"lon":62},[66],{"name":67,"role":48,"phone":68,"phoneExt":40,"email":50},"Suning Chen, PhD","+8613814881746",{"facility":70,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology",{"type":60,"coordinates":72},[62,63],{"lat":63,"lon":62},[75,78],{"name":76,"role":48,"phone":77,"phoneExt":40,"email":50},"Suning Chen, Professor","13814881746",{"name":76,"role":45,"phone":40,"phoneExt":40,"email":40},{"type":45,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"Chen Suning","Principal Investigator","100470365","phase-2-aza--venetoclax-as-maintenance-therapy-in-younger-adults-with-aml-in-first-remission-100470365",false,"NCT05404906","AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission","Randomized, Multicenter, Phase 3 Study of Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remissionin Younger Adults With Favorable-risk AML in First Remission After Conventional Chemotherapy","Inclusion Criteria:\n\n1. Diagnosis of favorable-risk acute myeloid leukemia (AML) according to revised 2017 European LeukemiaNet genetic risk stratification and are not immediate candidates for allogeneic stem cell transplant.\n2. Aged 18-64 years.\n3. Patients who have received remission induction therapy and 3-4 HiDAC or medium-dose cytarabine-based consolidation and are in their first remission.\n4. ECOG performance status of \\\u003C or = 3.\n5. Adequate organ function as follows:\n\n   1. Serum total bilirubin \\\u003C or = to 3 X the Upper Limit of Normal (ULN)\n   2. Aspartate Transaminase and alanine transaminase \\\u003C or = to 3 x ULN\n   3. Ccr（Creatinine Clearance Rate) \\> or ＝60 ml\u002Fmin\n   4. Left ventricular ejection fraction \\> or ＝50% determined by ultrasound.\n6. For females of childbearing age, they should have a negative serum or urine pregnancy test within 10 to 14 days of enrolling.\n7. For males of childbearing age, they should take effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment.\n8. Ability to understand and sign informed consent.\n\nExclusion Criteria:\n\n1. Acute promyeloid leukemia.\n2. Patients with active central nervous system (CNS) leukemia.\n3. Previously diagnosed with myelodysplastic syndrome (MDS) or myeloproliferative neoplasm(MPN) and progressed to AML.\n4. Patients with other progressive malignancies.\n5. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to uncontrolled and\u002For active systemic infection (viral, bacterial or fungal).\n6. Patients who have participated in other trials within 30 days before signing the informed consent.\n7. Females who are pregnant or lactating or intending to become pregnant during the study.","ALL","18 Years","64 Years",{"count":93,"type":94},124,"ESTIMATED","INTERVENTIONAL",[97,98],"PHASE2","PHASE3","This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.",[101],"Acute Myeloid Leukemia (AML) in Remission","2022-08-18",{"date":104,"type":105},"2022-08-19","ACTUAL",{"date":107,"type":105},"2022-06-25",{"date":109,"type":94},"2030-06",{"name":5,"class":6},2]